RxDoctor Payments Data

George Benchimol, MD

Family Medicine · Gainesville, FLNPI 1962461806

Payments from drug & device makers

$13,495in general payments, 2019–2025

Across 758 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • Lilly USA, LLC$2K
  • Amgen$1K
  • Boehringer Ingelheim$1K
  • Pfizer$889
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$13,476100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,495 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$297,635
Medicare patients
538
Services billed
6,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$170,100
JardianceEmpagliflozin93$125,535
OzempicSemaglutide85$100,781
MounjaroTirzepatide70$83,810
FarxigaDapagliflozin Propanediol65$75,918
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$29,791
JanuviaSitagliptin Phosphate32$25,200
VascepaIcosapent Ethyl29$22,250
EntrestoSacubitril/Valsartan13$19,087
XareltoRivaroxaban12$17,434
Breo ElliptaFluticasone/Vilanterol20$12,306
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,357
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$7,948
Atorvastatin Calcium710$6,316
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$5,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$889$170,100159 claims
Boehringer IngelheimJardiance$1,015$125,53593 claims
Novo NordiskOzempic$2,693$100,78185 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,619$84,27576 claims
Lilly USA, LLCMounjaro$1,598$83,81070 claims
GSKTrelegy Ellipta, Breo Ellipta$293$42,09853 claims
MerckJanuvia$258$25,20032 claims
NovartisEntresto$78$19,08713 claims
Johnson & JohnsonXarelto$36$17,43412 claims
Sanofi-aventis U.S. LLCLantus$71$2,57820 claims
AbbVieSynthroid$615$2,48327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →